What question did this study set out to answer?

To evaluate clinical outcomes in women with early breast cancer and a high 21-gene recurrence score who received adjuvant chemotherapy combined with endocrine therapy in the TAILORx trial.

October 1, 2019JAMA OncologyOpen Access

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy

View Full Paper

Ask AI

Bookmark

To evaluate clinical outcomes in women with early breast cancer and a high 21-gene recurrence score who received adjuvant chemotherapy combined with endocrine therapy in the TAILORx trial.
Secondary analysis of the TAILORx multicenter randomized clinical trial (NCT00310180) involving 1389 women with hormone receptor-positive, ERBB2-negative, axillary node-negative early breast cancer and a high recurrence score of 26 to 100.
Participants were prospectively assigned to receive physician-selected adjuvant chemotherapy regimens, predominantly taxane- and/or anthracycline-based, combined with endocrine therapy.
At 5 years, the estimated rate of freedom from distant recurrence was 93.0% (SE, 0.8%), and freedom from distant and/or locoregional recurrence was 91.0% (SE, 0.8%).
Estimated 5-year invasive disease-free survival was 87.6% (SE, 1.0%), and overall survival reached 95.9% (SE, 0.6%).
Chemotherapy regimens included docetaxel/cyclophosphamide in 589 patients (42%), an anthracycline without a taxane in 334 (24%), an anthracycline plus taxane in 244 (18%), and no chemotherapy in 89 (6%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial reveals 93% distant recurrence-free survival in high-recurrence-score breast cancer, indicating substantial chemotherapy benefit over endocrine therapy alone.

Cite This Study

Sparano et al. (2019) studied this question.

synapsesocial.com/papers/6a0b1baa334bc3615dacbca7 https://doi.org/10.1001/jamaoncol.2019.4794

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals 93% distant recurrence-free survival in high-recurrence-score breast cancer, indicating substantial chemotherapy benefit over endocrine therapy alone.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy

Key Points

Discussion

Implication

Cite This Study

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider